- The report contains detailed information about RTI Biologics, Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
- Another part of the report is a SWOT-analysis carried out for RTI Biologics, Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company’s strengths, weaknesses, opportunities, and possible threats against it.
- The RTI Biologics, Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency. This sort of company's information will assist and strengthen your company’s decision-making processes.
- In the part that describes RTI Biologics, Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company’s competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
- Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of RTI Biologics, Inc. business.
About RTI Biologics, Inc.
RTI Biologics, Inc. produces orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues and improve surgical outcomes.
The company processes human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue into allografts, and bovine animal tissue into xenografts, utilizing proprietary BIOCLEANSE and TUTOPLAST sterilization processes, for distribution to hospitals and surgeons. The company processes at two facilities in Alachua, Florida and one facility in Germany and distributes products and services in all 50 states and in approximately 31 countries worldwide.
The company processes human and bovine animal tissue and distributes the tissue through various distribution channels. Its lines of business are comprised primarily of six product categories: spine, sports medicine, dental, surgical specialties, bone graft substitutes, and general orthopedic.
The company has distribution arrangements with Medtronic (MDT); Zimmer, Inc. (Zimmer); Blackstone Medical, Inc., a subsidiary of Orthofix International NV (Blackstone); Stryker Spine, a division of Stryker (Stryker); and Aesculap Implant Systems, Inc. (Aesculap) for spine implants, and with Zimmer for dental implants. For surgical specialties markets, the company distributes through Davol, Inc., a subsidiary of C. R. Bard, Inc. (Davol), for hernia repair, and breast reconstruction, through Coloplast A/S of Denmark (Coloplast) for urology, through IOP, Inc. (IOP) for ophthalmology and through ENTrigue Surgical, Inc. (ENTrigue) for ENT applications. Zimmer, Stryker, Exactech, Inc., (Exactech) and Pioneer Surgical Technology, Inc. (Pioneer) are the companys distributors for allograft paste implants, and Wright Medical Technology, Inc. (Wright) distributes certain of sports medicine implants.
BioCleanse Tissue Sterilization Solution
The company has developed and utilized in the United States the patented BioCleanse tissue sterilization process, which is an automated, pharmaceutical grade chemical sterilization process for musculoskeletal bone and certain soft tissue. This process is fully validated to kill or inactivate all classes of conventional pathogens, viruses, microbes, bacteria and fungi. BioCleanse process is able to remove greater than 99% of the blood, fats, lipids and other unwanted materials from the tissue that the company processes. BioCleanse process is used on most of bone allografts and xenografts and most of musculoskeletal soft tissue products.
The TUTOPLAST Tissue Sterilization Solution
The TUTOPLAST tissue sterilization process utilizes solvent dehydration and chemical inactivation to remove blood, lipids and extraneous materials, inactivate viruses and prions, and break down RNA and DNA into fragments not capable of replication and disease transmission while preserving the biological and mechanical properties.
The company applies the TUTOPLAST process to two types of preserved allografts: soft tissue, consisting of fascia lata, fascia temporalis, pericardium, dermis and sclera; and bone tissue; consisting of various configurations of cancellous and cortical bone material.
Tissue recovery is the actual removal of tissue from a donor after receiving appropriate consent. Consent is obtained by the tissue recovery group. The company operates certain tissue recovery groups directly, and contract with other independent FDA registered tissue recovery groups which specialize in this activity. Tissue recovery personnel aseptically recover musculoskeletal tissue within 24 hours following a donors death, using surgical instruments and sterile techniques similar to those used in hospitals for routine surgery. Recovered tissue is placed on wet or dry ice and then transported by the donor recovery agency to the tissue processor or possibly a research institution.
The companys network of donor recovery groups recovers a variety of tissue types from donors, including the fibula, femur, tibia, humerus, ilium, pericardium, fascia lata, dermis, sclera, tendons and ligaments. It also performs biomedical testing and culturing at various stages during the processing of tissue, using FDA licensed tests and other tests for known viruses and pathogens.
The companys principal competitors in the conventional allograft market include the Musculoskeletal Transplant Foundation, or MTF; AlloSource, LifeCell, Inc., a subsidiary of Kinetic Concepts Inc.; and LifeNet. Among competitors in precision machined allograft are Osteotech, MTF, LifeNet and AlloSource. Other companies who process and distribute allograft pastes include Osteotech, AlloSource, Integra, Wright, and MTF. Companies who process and distribute xenograft tissue include Synovis, LifeCell, Cook Surgical and Osteotech.
RTI Biologics, Inc. was founded in 1997. It was formerly known as Regeneration Technologies, Inc. and changed its name to RTI Biologics, Inc. in 2008.
The above Company Fundamental Report is a half-ready report and contents are subject to change.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.
1. RTI BIOLOGICS, INC. COMPANY PROFILE
1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History
2. RTI BIOLOGICS, INC. BUSINESS OVERVIEW
2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units
3. RTI BIOLOGICS, INC. SWOT ANALYSIS
4. RTI BIOLOGICS, INC. FINANCIAL ANALYSIS
4.1. Financial Statements
4.1.1. Income Statement
4.1.2. Balance Sheet
4.1.3. Cash Flow
4.2. Financial Ratios
4.2.2. Margin Analysis
4.2.3. Asset Turnover
4.2.4. Credit Ratios
4.2.5. Long-Term Solvency
4.2.6. Growth Over Prior Year
4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot
5. RTI BIOLOGICS, INC. COMPETITORS AND INDUSTRY ANALYSIS
5.1. RTI Biologics, Inc. Direct Competitors
5.2. Comparison of RTI Biologics, Inc. and Direct Competitors Financial Ratios
5.3. Comparison of RTI Biologics, Inc. and Direct Competitors Stock Charts
5.4. RTI Biologics, Inc. Industry Analysis
5.4.1. Healthcare Equipment/Supplies Industry Snapshot
5.4.2. RTI Biologics, Inc. Industry Position Analysis
6. RTI BIOLOGICS, INC. NEWS & EVENTS
6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events
7. RTI BIOLOGICS, INC. EXPERTS REVIEW1
7.1. Experts Opinion
7.2. Experts Estimates
8. RTI BIOLOGICS, INC. ENHANCED SWOT ANALYSIS2
9. UNITED STATES PESTEL ANALYSIS2
9.1. Political Factors
9.2. Economic Factors
9.3. Social Factors
9.4. Technological Factors
9.5. Environmental Factors
9.6. Legal Factors
10. RTI BIOLOGICS, INC. IFE, EFE, IE MATRICES2
10.1. Internal Factor Evaluation Matrix
10.2. External Factor Evaluation Matrix
10.3. Internal External Matrix
11. RTI BIOLOGICS, INC. PORTER FIVE FORCES ANALYSIS2
12. RTI BIOLOGICS, INC. VRIO ANALYSIS2
APPENDIX: RATIO DEFINITIONS
LIST OF TABLES
RTI Biologics, Inc. Key Facts
Income Statement Key Figures
Balance Sheet Key Figures
Cash Flow Statement Key Figures
Financial Performance Abbreviation Guide
RTI Biologics, Inc. Key Executives
Key Executives Biographies1
Key Executives Compensations1
RTI Biologics, Inc. Major Shareholders
RTI Biologics, Inc. History
RTI Biologics, Inc. Products
Revenues by Segment
Revenues by Region
RTI Biologics, Inc. Offices and Representations
RTI Biologics, Inc. SWOT Analysis
Yearly Income Statement Including Trends
Income Statement Latest 4 Quarters Including Trends
Yearly Balance Sheet Including Trends
Balance Sheet Latest 4 Quarters Including Trends
Yearly Cash Flow Including Trends
Cash Flow Latest 4 Quarters Including Trends
RTI Biologics, Inc. Profitability Ratios
Margin Analysis Ratios
Asset Turnover Ratios
Long-Term Solvency Ratios
Financial Ratios Growth Over Prior Year
RTI Biologics, Inc. Capital Market Snapshot
RTI Biologics, Inc. Direct Competitors Key Facts
Direct Competitors Profitability Ratios
Direct Competitors Margin Analysis Ratios
Direct Competitors Asset Turnover Ratios
Direct Competitors Credit Ratios
Direct Competitors Long-Term Solvency Ratios
Healthcare Equipment/Supplies Industry Statistics
RTI Biologics, Inc. Industry Position
Company vs. Industry Income Statement Analysis
Company vs. Industry Balance Sheet Analysis
Company vs. Industry Cash Flow Analysis
Company vs. Industry Ratios Comparison
RTI Biologics, Inc. Consensus Recommendations1
Analyst Recommendation Summary1
Price Target Summary1
Experts Recommendation Trends1
Revenue Estimates Analysis1
Earnings Estimates Analysis1
Revenue Estimates Trend1
Earnings Estimates Trend1
LIST OF FIGURES
RTI Biologics, Inc. Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Profit Margin Chart
Operating Margin Chart
Return on Equity (ROE) Chart
Return on Assets (ROA) Chart
Debt to Equity Chart
Current Ratio Chart
RTI Biologics, Inc. 1-year Stock Charts
RTI Biologics, Inc. 5-year Stock Charts
RTI Biologics, Inc. vs. Main Indexes 1-year Stock Chart
RTI Biologics, Inc. vs. Direct Competitors 1-year Stock Charts
RTI Biologics, Inc. Article Density Chart
1 – Data availability depends on company’s security policy.
2 – These sections are available only when you purchase a report with appropriate additional types of analyses.
The complete financial data is available for publicly traded companies.
SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.
Enhanced SWOT Analysis
Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:
- How to use the strengths to take advantage of the opportunities?
- How to use the strengths to reduce likelihood and impact of the threats?
- How to overcome the weaknesses that obstruct taking advantage of the opportunities?
- How to overcome the weaknesses that can make the threats a reality?
Upon answering these questions a company can develop a project plan to improve its business performance.
PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.
Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.
Key Factors Examined by PESTEL Analysis:
- Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations’ impact on the business?
- Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence’s degree?
- Sociological – What cultural and societal aspects will work upon the demand for the business’s products and operations?
- Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?
- Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?
- Legal – What laws and legislation will exert influence on the style the business is carried out?
IFE, EFE, IE Matrices
The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business’s functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.
The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.
The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.
Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors integrated into one suggestive model.
Porter Five Forces Analysis
The Porter’s five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:
- What composes a threat of substitute products and services?
- Is there a threat of new competitors entering the market?
- What is the intensity of competitive rivalry?
- How big is the bargaining power of buyers?
- How significant is the bargaining power of suppliers?
VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company’s resources and capabilities and bring them together into one aggregate table that includes:
- Tangible resources
- Intangible resources
- Innovation and Creativity
- Organizational capabilities
The result of the analysis gives a clear picture of company’s competitive and economic implications, answering the questions if the resources mentioned above are:
- Costly to imitate?
- Organized properly?